Browsing by Issue Date, starting with "2024-02-25"
Now showing 1 - 1 of 1
Results Per Page
Sort Options
- Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital networkPublication . Rose, Angela M. C.; Pozo, Francisco; Martínez‐Baz, Iván; Mazagatos, Clara; Bossuyt, Nathalie; Cauchi, John Paul; Petrović, Goranka; Loghin, Isabela I.; Vaikutyte, Roberta; Buda, Silke; Machado, Ausenda; Duffy, Róisín; Oroszi, Beatrix; Howard, Jennifer; Echeverria, Aitziber; Andreu, Cristina; Barbezange, Cyril; Džiugytė, Aušra; Nonković, Diana; Popescu, Corneliu‐Petru; Majauskaite, Fausta; Tolksdorf, Kristin; Gómez, Verónica; Domegan, Lisa; Horváth, Judit Krisztina; Castilla, Jesús; García, Miriam; Demuyser, Thomas; Borg, Maria‐Louise; Tabain, Irena; Lazar, Mihaela; Kubiliute, Ieva; Dürrwald, Ralf; Guiomar, Raquel; O'Donnell, Joan; Kristóf, Katalin; Nicolay, Nathalie; Bacci, Sabrina; Kissling, Esther; VEBIS SARI VE network team; Belgium SARI Surveillance Network (BelsariNet)We conducted a multicentre hospital-based test-negative case–control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI: −23–36); 20% (95% CI: −4–39) against A(H3N2) and 56% (95% CI: 22–75) against B. During the 2022/2023 season, while VE against hospitalisation with influenza B was >55%, it was ≤20% for influenza A subtypes. While influenza vaccination should be a priority for future seasons, improved vaccines against influenza are needed.